with a transcription product of AIM gene, and/or
(b) antibody to AIM.

23. The kit according to claim 22, wherein the kidney disease is acute renal failure, chronic nephritis, chronic renal failure, nephrotic syndrome, diabetic nephropathy, nephrosclerosis, IgA nephropathy, hypertensive nephropathy, nephropathy associated with a collagen disease or IgM nephropathy.

~~24. A method for the prophylaxis or treatment of a kidney disease, comprising administering an effective amount of AIM or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same to a subject.~~

~~25. A method for the prophylaxis or treatment of a kidney disease, comprising administering an effective amount of a drug that induces AIM expression or a drug that stabilizes AIM to a subject.~~

~~26. The method according to claim 24 or 25, wherein the kidney disease is acute renal failure, chronic nephritis, chronic renal failure, nephrotic syndrome, diabetic nephropathy, nephrosclerosis, IgA nephropathy, hypertensive nephropathy, nephropathy associated with a collagen disease or IgM nephropathy.~~

~~27. The method according to any one of claims 24 to 26, wherein the kidney disease is acute renal failure or chronic renal failure.~~

~~28. The method according to any one of claims 24 to 27, wherein the subject of prophylaxis or treatment is a human.~~

~~29. The method according to any one of claims 24 to 27, wherein~~

~~the subject of prophylaxis or treatment is a cat.~~

~~30. The method according to claim 29 wherein the AIM or a partial peptide thereof binds to cat IgM.~~

~~31~~24. AIM or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, for use in the prophylaxis or treatment of a kidney disease.

~~32~~25. The AIM or a partial peptide thereof or a nucleic acid comprising a base sequence encoding the same according to claim 31, wherein the kidney disease is acute renal failure, chronic nephritis, chronic renal failure, nephrotic syndrome, diabetic nephropathy, nephrosclerosis, IgA nephropathy, hypertensive nephropathy, nephropathy associated with a collagen disease or IgM nephropathy.

~~33~~26. The AIM or a partial peptide thereof or a nucleic acid comprising a base sequence encoding the same according to claim 31 or 32, wherein the kidney disease is acute renal failure or chronic renal failure.

~~34~~27. The AIM or a partial peptide thereof or a nucleic acid comprising a base sequence encoding the same according to any one of claims 31 to 33, wherein the subject of prophylaxis or treatment is a human.

~~35~~28. The AIM or a partial peptide thereof or a nucleic acid comprising a base sequence encoding the same according to any one of claims 31 to 33, wherein the subject of prophylaxis or treatment is a cat.

~~36~~29. The AIM or a partial peptide thereof or a nucleic acid comprising a base sequence encoding the same according to claim 35, wherein the AIM or a partial peptide thereof binds to cat

IgM.

~~37~~30. A drug that induces AIM expression or a drug that stabilizes AIM, for use in the prophylaxis or treatment of a kidney disease.

~~38~~31. The drug that induces AIM expression or the drug that stabilizes AIM according to claim ~~37~~30, wherein the kidney disease is acute renal failure, chronic nephritis, chronic renal failure, nephrotic syndrome, diabetic nephropathy, nephrosclerosis, IgA nephropathy, hypertensive nephropathy, nephropathy associated with a collagen disease or IgM nephropathy.

~~39~~32. The drug that induces expression of AIM or the drug that stabilizes AIM according to claim ~~37~~ 30 or ~~38~~31, wherein the kidney disease is acute renal failure or chronic renal failure.

~~40~~33. The drug that induces expression of AIM or the drug that stabilizes AIM according to any one of claims ~~37~~ 30 to ~~39~~32, wherein the subject of prophylaxis or treatment is a human.

~~41~~34. The drug that induces expression of AIM or the drug that stabilizes AIM according to any one of claims ~~37~~ 30 to ~~39~~32, wherein the subject of prophylaxis or treatment is a cat.

~~42~~35. The drug that induces expression of AIM or the drug that stabilizes AIM according to claim ~~41~~34, wherein the AIM or a partial peptide thereof binds to cat IgM.

~~43~~36. Use of AIM or a partial peptide thereof or a nucleic acid comprising a base sequence encoding the same or a drug that induces expression of AIM or a drug that stabilizes AIM, which is for the production of a prophylactic or therapeutic agent for a kidney disease.

~~44~~37. The use according to claim ~~43~~36, wherein the kidney disease is acute renal failure, chronic nephritis, chronic renal failure, nephrotic syndrome, diabetic nephropathy, nephrosclerosis, IgA nephropathy, hypertensive nephropathy, nephropathy associated with a collagen disease or IgM nephropathy.

~~45~~38. The use according to claim ~~43~~36 or ~~44~~37, wherein the kidney disease is acute renal failure or chronic renal failure.

~~46~~39. The use according to any one of claims ~~43~~36 to ~~45~~38, wherein the subject of prophylaxis or treatment is a human.

~~47~~40. The use according to any one of claims ~~43~~36 to ~~45~~38, wherein the subject of prophylaxis or treatment is a cat.

~~48~~41. The use according to claim ~~47~~40, wherein the AIM or a partial peptide thereof binds to cat IgM.